Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 90 | Retinitis pigmentosa | 1 |
90. Retinitis pigmentosa
Clinical trials : 147 / Drugs : 176 - (DrugBank : 43) / Drug target genes : 49 - Drug target pathways : 110
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01482195 (ClinicalTrials.gov) | August 2011 | 28/9/2011 | Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK) | Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK Mutations | Retinal Disease;Retinitis Pigmentosa | Biological: Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus | King Khaled Eye Specialist Hospital | King Faisal Specialist Hospital & Research Center | Completed | 14 Years | 70 Years | All | 6 | Phase 1 | Saudi Arabia |